Archive: 12/09/2012
A large-scale trial testing the intensity of cytoreductive therapy to prevent cardiovascular events
In the first randomized clinical trial assessing the proper target hematocrit level, or percentage of red blood cells that should be maintained in patients with polycythemia vera (PV), researchers have concluded that the ...
Medical research
Dec 09, 2012 |
not rated yet |
0
Studies assess genetics, modified treatment to improve outcomes, reduce toxicity
Research identifying genetic factors that affect survival of patients with blood cancers and evaluating the effectiveness of modified treatment strategies to improve outcomes while reducing toxicity will be presented today ...
Cancer
Dec 09, 2012 |
5 / 5 (1) |
0
Pre-clinical data shows Angiocidin effective against leukemia
Angiocidin, a novel tumor-inhibiting protein, has been shown to reduce acute myeloid leukemia (AML) cells in vivo by almost two-thirds in pre-clinical experiments.
Cancer
Dec 09, 2012 |
not rated yet |
0
Genetic susceptibility to anthracycline-related congestive heart failure (CHF) in survivors of hematopoietic cell transp
Researchers have identified specific genetic factors that are associated with heart failure in patients who have undergone hematopoietic stem cell transplantation (HCT) for blood cancer.
Medical research
Dec 09, 2012 |
not rated yet |
0
Genotype predicts treatment related mortality (TRM) in African-American and Asian pediatric AML patients
New research suggests that the presence of a specific genetic marker, known as WT1 SNP rs16754, may be associated with reduced toxicity from chemotherapy in African-American and Asian children with acute myeloid leukemia ...
Cancer
Dec 09, 2012 |
not rated yet |
0
Updated clinical results show experimental agent ibrutinib as highly active in CLL patients
Updated results from a Phase Ib/II clinical trial indicates that a novel therapeutic agent for chronic lymphocytic leukemia (CLL) is highly active and well tolerated in patients who have relapsed and are resistant to other ...
Cancer
Dec 09, 2012 |
not rated yet |
0
ATRA and arsenic trioxide versus ATRA and idarubicin for newly diagnosed, non high-risk acute promyelocytic
New research demonstrates the efficacy of the first curative treatment for acute promyelocytic leukemia (APL) that does not include chemotherapy, marking an important step toward front-line use of targeted therapies for acute ...
Cancer
Dec 09, 2012 |
not rated yet |
0
Researchers develop novel 3-D culture system for inflammatory breast cancer
Inflammatory breast cancer (IBC) is a very rare and aggressive disease that progresses rapidly and is associated with a very low survival rate. To understand how this type of cancer spreads, it's crucial to characterize the ...
Cancer
Dec 09, 2012 |
not rated yet |
0
|
